Equities

Oneview Healthcare PLC

Oneview Healthcare PLC

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.305
  • Today's Change-0.01 / -3.17%
  • Shares traded261.07k
  • 1 Year change+52.50%
  • Beta2.5449
Data delayed at least 20 minutes, as of Nov 22 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast

The 2 analysts offering 12 month price targets for Oneview Healthcare PLC have a median target of 0.3217, with a high estimate of 0.3217 and a low estimate of 0.3217. The median estimate represents a 5.48% increase from the last price of 0.305.
High5.5%0.3217
Med5.5%0.3217
Low5.5%0.3217

Earnings history & estimates in EUR

Oneview Healthcare PLC reported annual 2018 losses of -0.247 per share on Feb 27, 2019.
Average growth rate-2.05%
More ▼

Revenue history & estimates in EUR

Oneview Healthcare PLC had revenues for the full year 2018 of 8.20m. This was 29.89% above the prior year's results.
Average growth rate-0.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.